The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Open accessAbstract
BACKGROUND: Type 1 diabetes is a chronic autoimmune disease that leads to destruction of insulin-producing beta cells and dependence on exogenous insulin for survival. Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. METHODS: We conducted a phase 2, randomized, placebo-controlled, double-blind trial of teplizumab (an Fc receptor-nonbinding anti-CD3 monoclonal antibody) involving relatives of patients with type 1 diabetes who did not have diabetes but were at high risk for development of clinical disease. Patients were randomly assigned to a single 14-day course of teplizumab or placebo, and follow-up for progression to clinical type 1 diabetes was performed with the use of oral glucose-tolerance tests at 6-month intervals. RESULTS: A total of 76 participants (55 [72%] of whom were ≤18 years of age) underwent randomization - 44 to the teplizumab group and 32 to the placebo group. The median time to the diagnosis of type 1 diabetes was 48.4 months in the teplizumab group and 24.4 months in the placebo group; the disease was diagnosed in 19 (43%) of the participants who received teplizumab and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (teplizumab vs. placebo) was 0.41 (95% confidence interval, 0.22 to 0.78; P = 0.006 by adjusted Cox proportional-hazards model). The annualized rates of diagnosis of diabetes were 14.9% per year in the teplizumab group and 35.9% per year in the placebo group. There were expected adverse events of rash and transient lymphopenia. KLRG1+TIGIT+CD8+ T cells were more common in the teplizumab group than in the placebo group. Among the participants who were HLA-DR3-negative, HLA-DR4-positive, or anti-zinc transporter 8 antibody-negative, fewer participants in the teplizumab group than in the placebo group had diabetes diagnosed. CONCLUSIONS: Teplizumab delayed progression to clinical type 1 diabetes in high-risk participants. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01030861.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Family history of autoimmune diabetes and personal or family history of allergic diseases or other autoimmune diseases increases the risk of autoimmune diabetes compared with the general population (78,79).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, anti-CD3 treatment (teplizumab) has been shown to induce long-term protection (currently up to six years) from T1D in at-risk individuals, but the mechanisms responsible for this long-term protection remain incompletely understood29,30”
From An autoimmune stem-like CD8 T cell population drives type 1 diabetes (2022) · cites this paper as [29]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The CD3 monoclonal antibody teplizumab has been shown to delay progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“there is now evidence that the anti-CD3 monoclonal antibody teplizumab delays progression to type 1 diabetes in high-risk individuals (429).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [429]
The cited source says what the claim attributes to it.
In the citing paper
“In one 2019 study with a 2year delay, annualised rates of clinical diabetes were 15% in the teplizumab group and 36% in the placebo group (table 1). 18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Teplizumab delays the onset of clinical type 1 diabetes by a median of 24 months.18”
From The future of type 1 diabetes therapy (2025) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,516
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
(2018) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,855
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.11.006 · Cited by 1,355
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254 · cited 2×
“Three participants in the teplizumab group and 4 participants in the placebo group did not complete the trial regimen; the reasons were laboratory abnormalities (4 participants), an inability to have intravenous access established (2), or rash (1).”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,000
Liu, T., Zhu, C., Duan, Z., Ma, P., Ma, X., & Fan, D. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c04949 · Cited by 14
Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan, A. J., Gorelik, S., & Nally, L. M. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1477101 · Cited by 14
Sundheim, B., Hirani, K., Blaschke, M., Lemos, J. R. N., & Mittal, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020383 · Cited by 15
Immunotherapies for prevention and treatment of type 1 diabetes
Jeun, R. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2473311 · Cited by 18
Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes
Lord, S. M., & Greenbaum, C. J. (2020) · F1000Research · doi:10.12688/f1000research.21801.1 · Cited by 15
Self-citationFelton, J. L., Conway, H., & Bonami, R. H. (2021) · Biomedicines · doi:10.3390/biomedicines9010042 · Cited by 13
Transforming type 1 diabetes: the next wave of innovation
Drucker, D. J. (2021) · Diabetologia · doi:10.1007/s00125-021-05396-5 · Cited by 16
Cortez, F. D. J., Gebhart, D., Tandel, D., Robinson, P. V., Seftel, D., Wilson, D. M., Maahs, D. M., Buckingham, B. A., Miller, K. W. P., & Tsai, C.-T. (2022) · SLAS TECHNOLOGY · doi:10.1016/j.slast.2021.10.001 · Cited by 16
Advances in Immunotherapeutic Approaches to Type 1 Diabetes
Cudini, A., & Fierabracci, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119220 · Cited by 15
Michels, A. W., Brusko, T. M., Evans‐Molina, C., Homann, D., Richardson, S. J., & Powers, A. C. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf267 · Cited by 16
Trained immunity: novel perspectives in diabetes and associated complications
Liu, Y., Lei, Y., Dai, Z., Luo, C., Gong, Q., Li, Y., Xu, Y., & Huang, W. G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613602 · Cited by 14
Gitelman, S. E., Simmons, K. M., Sherr, J. L., Leichter, S. B., Quattrin, T., Russell, W. E., Sunil, B., Willi, S. M., Knecht, L. A., Niemoeller, E., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06586-1 · Cited by 15
Self-citationXie, Q. Y., Oh, S., Wong, A., Yau, C., Herold, K. C., & Danska, J. S. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh0353 · Cited by 15
Self-citationFanaropoulou, N. M., Tsatsani, G. C., Koufakis, T., & Kotsa, K. (2023) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2281990 · Cited by 14
TMEM219 regulates the transcription factor expression and proliferation of beta cells
D’Addio, F., Assi, E., Maestroni, A., Rossi, G., Usuelli, V., Petrazzuolo, A., Nardini, M., Loretelli, C., Nasr, M. B., & Fiorina, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1306127 · Cited by 12
Temporal Alterations in CD8+ T Cells During the Progression From Stage 1 to Stage 3 Type 1 Diabetes
Schroderus, A., Pitkänen, V., Ekman, I., Stevens, D., Rytkönen-Nissinen, M. A., Rintamäki, R. M., Pihlajamäki, J., Knip, M., Veijola, R., Toppari, J., et al. (2024) · Diabetes · doi:10.2337/db24-0159 · Cited by 14
Li, X., Zhou, X., Huang, T., Jiang, Y., Wan, H., Zhang, D., Ling, J., Wu, Y., Liu, X., Yang, P., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102473 · Cited by 13
Type 1 diabetes: immune pathology and novel therapeutic approaches
Ling, E. M., Lemos, J. R. N., Hirani, K., & von Herrath, M. (2024) · Diabetology International · doi:10.1007/s13340-024-00748-z · Cited by 13
Time to reframe the disease staging system for type 1 diabetes
Jacobsen, L. M., Atkinson, M. A., Sosenko, J. M., & Gitelman, S. E. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00239-0 · Cited by 15
Self-citationThe extra-islet pancreas supports autoimmunity in human type 1 diabetes
Barlow, G. L., Schürch, C. M., Bhate, S. S., Phillips, D. J., Young, A., Dong, S., Martinez, H., Kaber, G., Nagy, N., Ramachandran, S., et al. (2025) · eLife · doi:10.7554/elife.100535.3 · Cited by 13
Self-citationExploring new frontiers in LAG-3 biology and therapeutics
Wang, J., Klein, C., Cochran, J. R., Sockolosky, J. T., & Lippow, S. M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.05.008 · Cited by 13
Nelson, B., Amminger, G. P., Bechdolf, A., French, P., MALLA, A. K., Morrison, A. P., Schmidt, S. J., Shah, J. L., Thompson, A. D., van der Gaag, M., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30513-9 · Cited by 13
Buschard, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.876470 · Cited by 15
Liu, Y., Li, W., Chen, Y., & Wang, X. (2023) · Endocrine · doi:10.1007/s12020-023-03499-0 · Cited by 13
Camaya, I., Mok, T. Y., Lund, M. E., To, J., Braidy, N., Robinson, M. W., Santos, J., O’Brien, B. A., & Donnelly, S. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02122-x · Cited by 12
Detecting insulitis in type 1 diabetes with ultrasound phase-change contrast agents
Ramirez, D. G., Ciccaglione, M., Upadhyay, A., Pham, V. T., Borden, M. A., & Benninger, R. K. P. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022523118 · Cited by 13
Accili, D. (2020) · New England Journal of Medicine · doi:10.1056/nejme2030472 · Cited by 13
Screening children for type 1 diabetes
Besser, R. E. J., Ng, S. M., & Robertson, E. J. (2021) · BMJ · doi:10.1136/bmj-2021-067937 · Cited by 14
Arena, A., Belcastro, E., Ceccacci, F., Petrini, S., Conti, L. A., Pagliarosi, O., Giorda, E., Sennato, S., Schiaffini, R., Wang, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838331 · Cited by 12
Guertin, K. A., Repaske, D. R., Taylor, J. F., Williams, E. S., Önengüt-Gümüşcü, S., Chen, W., Boggs, S. R., Yu, L., Allen, L., Botteon, L., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01305-8 · Cited by 13
Cell-Surface ZnT8 Antibody Prevents and Reverses Autoimmune Diabetes in Mice
Kasinathan, D., Guo, Z., Sarver, D. C., Wong, G. W., Yun, S., Michels, A. W., Yu, L., Sona, C., Poy, M. N., Golson, M. L., et al. (2024) · Diabetes · doi:10.2337/db23-0568 · Cited by 12
Alves, G. G., Cunha, L., Machado, R. H., & de Menezes, V. L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15581 · Cited by 12
Feng, X., Zhang, H., Yang, S., Cui, D., Wu, Y., Qi, X., & Su, Z. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04999-x · Cited by 13
Imaging abnormalities of the pancreas in diabetes: implications for diagnosis and treatment
Spilseth, B., Fogel, E. L., Toledo, F. G. S., & Campbell‐Thompson, M. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001054 · Cited by 13
Prediction and Prevention of Inflammatory Bowel Disease
Lopes, E. W., Turpin, W., Croitoru, K., Colombel, J., & Torres, J. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.05.047 · Cited by 13
Kakabadse, D., Chen, D., Fishman, S., Weinstein-Marom, H., Davies, J. E., Li, W., Gross, G., & Wong, F. S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1463971 · Cited by 12
Therapy concepts in type 1 diabetes mellitus treatment: disease modifying versus curative approaches
Lenzen, S., & Jörns, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02494-w · Cited by 13
12-Lipoxygenase inhibition delays onset of autoimmune diabetes in human gene replacement mice
Nargis, T., Muralidharan, C., Enriquez, J. R., Wang, J. E., Kaylan, K. B., Chakraborty, A., Pratuangtham, S., Figatner, K. T., Nelson, J. B., May, S. C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.185299 · Cited by 11
Stewart, J. M., Posgai, A. L., Leon, J., Haller, M. J., & Keselowsky, B. G. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01075 · Cited by 12
Zinc transporter 8 autoantibody testing requires age-related cut-offs
Grace, S. L., Cooper, A., Jones, A. G., & McDonald, T. J. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002296 · Cited by 13
Voss, M. G., Cuthbertson, D. D., Cleves, M., Xu, P., Evans‐Molina, C., Palmer, J. P., REDONDO, M. J., Steck, A. K., Lundgren, M., Larsson, H. E., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0226 · Cited by 13
Self-citationAssociation of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes
Triolo, T. M., Pyle, L. L., BRONCUCIA, H. C., Armstrong, T., Yu, L., Gottlieb, P. A., & Steck, A. K. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab853 · Cited by 13
Self-citationFalahee, M., & Raza, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.883287 · Cited by 12
Galderisi, A., Evans‐Molina, C., Martino, M., Caprio, S., Cobelli, C., & Moran, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac740 · Cited by 13
Self-citationPrecision Medicine in Type 1 Diabetes
Michalek, D. A., Önengüt-Gümüşcü, S., Repaske, D. R., & Rich, S. S. (2023) · Journal of the Indian Institute of Science · doi:10.1007/s41745-023-00356-x · Cited by 14
Teplizumab: type 1 diabetes mellitus preventable?
Misra, S., & Shukla, A. K. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03474-8 · Cited by 13
Type 1 diabetes and inborn errors of immunity: Complete strangers or 2 sides of the same coin?
Mancuso, G., Genzano, C. B., Fierabracci, A., & Fousteri, G. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.03.026 · Cited by 12
Morales, J. F., Muse, R., Podichetty, J. T., Burton, J. K., David, S. E., Lang, P. M., Schmidt, S., Romero, K., O’Doherty, I. M., Martin, F., et al. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12973 · Cited by 12
Nassar, M., Chaudhuri, A., Ghanim, H., & Dandona, P. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i2.133 · Cited by 12
The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes
Nakayasu, E. S., Qian, W., Evans‐Molina, C., Mirmira, R. G., Eizirik, D. L., & Metz, T. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1634548 · Cited by 14
Quang, C. T., Zaniboni, B., Humeau, R., Lengliné, É., Dourthe, M.-É., Ganesan, R., Singh, S., Scheer, J. M., Asnafi, V., & Ghysdael, J. (2020) · Blood · doi:10.1182/blood.2019003801 · Cited by 12
From Prediction to Prevention: The Intricacies of Islet Autoantibodies in Type 1 Diabetes
Khine, A., & Quandt, Z. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01595-1 · Cited by 12
Karakus, K. E., Chesshir, L., Walker, S., Baschal, E. E., McDaniel, K. A., Triolo, T. M., Steck, A. K., Frohnert, B. I., Gottlieb, P. A., Michels, A. W., et al. (2026) · Diabetologia · doi:10.1007/s00125-025-06646-6 · Cited by 14
Self-citationShi, Y., Feng, Y., Li, T., Wu, J., Ling, Q., Guo, M., Fu, T., Nie, T., Ji, J., Meng, X., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00423-1 · Cited by 13
Lozano, I., Sork, H., Stone, V. M., Eldh, M., Cao, X., Pernemalm, M., Gabrielsson, S., & Flodström‐Tullberg, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.971313 · Cited by 11
Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review
Buddhavarapu, V., Dhillon, G., Grewal, H., Sharma, P., Kashyap, R., & Surani, S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i8.1793 · Cited by 11
Stefanaki, C., Rozou, P., Efthymiou, V., Xinias, I., Mastorakos, G. P., Bacopoulou, F., & Papagianni, M. (2024) · Nutrients · doi:10.3390/nu16162629 · Cited by 14
Huber, E., Singh, T., Bunk, M., Hebel, M., Kick, K., Weiß, A., Kohls, M., Köger, M., Hergl, M., Zapardiel‐Gonzalo, J., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae691 · Cited by 12
Self-citationBrown, M. E., Thirawatananond, P., Peters, L. D., Kern, E. J., Vijay, S., Sachs, L. K., Posgai, A. L., Brusko, M., Shapiro, M. R., Mathews, C. E., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06329-8 · Cited by 13
Teplizumab: a promising intervention for delaying type 1 diabetes progression
Saleem, M. R., & Khan, M. T. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1533748 · Cited by 11
Villalba, A., Rodríguez-Fernández, S., Perna‐Barrull, D., Ampudia, R.-M., Gómez-Muñoz, L., Pujol‐Autonell, I., Aguilera, E., Risueño, R. M., Cano‐Sarabia, M., Maspoch, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76041-1 · Cited by 10
Inflammasomes and Type 1 Diabetes
Pearson, J. A., Wong, F. S., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.686956 · Cited by 11
Karpen, S. R., Dunne, J. L., Frohnert, B. I., Marinac, M., Richard, C., David, S. E., & O’Doherty, I. M. (2022) · Diabetologia · doi:10.1007/s00125-022-05751-0 · Cited by 12
Monitoring immunomodulation strategies in type 1 diabetes
Krishnamurthy, B., Lacorcia, M., Kay, T. W. H., Thomas, H. E., & Mannering, S. I. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1206874 · Cited by 12
Lewis, E. L., Reichenberger, E. R., Anton, L., Gonzalez, M. V., Taylor, D. M., Porrett, P. M., & Elovitz, M. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256453 · Cited by 11
Translation of cell therapies to treat autoimmune disorders
Mehta, J. M., Hiremath, S. C., Chilimba, C., Ghasemi, A., & Weaver, J. D. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115161 · Cited by 11
Bombaci, B., Passanisi, S., Pecoraro, M., Sorrenti, L., Papa, M., Salzano, G., & Lombardo, F. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02245-w · Cited by 11
Admin, A., Russo, F., Citro, A., Squeri, G., Sanvito, F., Monti, P., Gregori, S., RONCAROLO, M. G., & Annoni, A. (2020) · Diabetes · doi:10.2337/db19-1249 · Cited by 12
Insulin immunotherapy for pretype 1 diabetes
Jacobsen, L. M., & Schatz, D. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000648 · Cited by 11
Self-citationEtiology and Pathogenesis of Diabetes Mellitus in Children and Adolescents
Yau, M., Maclaren, N. K., & Sperling, M. A. (2021) · Europe PMC (PubMed Central) · Cited by 11
Practical Clinical Applications of Islet Autoantibody Testing in Type 1 Diabetes
Winter, W. E., Pittman, D. L., & Jialal, I. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab113 · Cited by 11
Hussain, S., Tree, T. I. M., Mathieu, C., Klupa, T., Tuomaala, A., de Wit, M. V. M., Kordonouri, O., Braune, K., Pall, J., Castano, L., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70569 · Cited by 11
Kahn, S. E., Anderson, C. A. M., Buse, J. B., & Selvin, E. (2026) · Diabetes Care · doi:10.2337/dci26-0068 · Cited by 10
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes
Pribitzer, S., O’Rourke, C., Ylescupidez, A., Smithmyer, M. E., Bender, C., Speake, C., Lord, S. M., & Greenbaum, C. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae292 · Cited by 12
Self-citationJamadade, P., Nupur, N., Maharana, K. C., & Singh, S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01228-0 · Cited by 11
Quinn, L. M., Dias, R. P., Bidder, C., Bhowmik, S., Bumke, K., Ganapathi, J., Gorman, S., Hind, E., Karandikar, S., Kumar, K. B., et al. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004480 · Cited by 16
Emerging Concepts and Success Stories in Type 1 Diabetes Research: A Road Map for a Bright Future
Mallone, R., Sims, E. K., Achenbach, P., Mathieu, C., Pugliese, A., Atkinson, M. A., Dutta, S., Evans‐Molina, C., Klatzmann, D., Koralova, A., et al. (2024) · Diabetes · doi:10.2337/db24-0439 · Cited by 10
Self-citationREDONDO, M. J., Cuthbertson, D. D., Steck, A. K., Herold, K. C., Oram, R. A., Atkinson, M. A., Brusko, T. M., Parikh, H. M., Krischer, J. P., Önengüt-Gümüşcü, S., et al. (2024) · Diabetologia · doi:10.1007/s00125-024-06338-7 · Cited by 13
Self-citationType 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter
Ferrat, L. A., Templeman, E. L., Steck, A. K., Parikh, H. M., You, L., Önengüt-Gümüşcü, S., Gottlieb, P. A., Triolo, T. M., Rich, S. S., Krischer, J. P., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06434-2 · Cited by 11
Self-citationNimri, R., & Phillip, M. (2025) · Hormone Research in Paediatrics · doi:10.1159/000546713 · Cited by 13
Challenges in realizing therapeutic antibody biosensing
Nagata, M., Wilson, E. D., Ikebukuro, K., & Sode, K. (2025) · Trends in biotechnology · doi:10.1016/j.tibtech.2025.07.003 · Cited by 10
Oh, E., McCown, E. M., Ahn, M., Garcia, P. A., Branciamore, S., Tang, S., Zeng, D., Roep, B. O., & Thurmond, D. C. (2021) · Diabetes · doi:10.2337/db21-0170 · Cited by 10
Zhao, L. P., Skyler, J. S., Papadopoulos, G. K., Pugliese, A., Najera, J. A., Bondinas, G. P., Moustakas, A. K., Wang, R., Pyo, C., Nelson, W. C., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1628 · Cited by 11
Self-citationEthics of Early Clinical Trials of Bio-Artificial Organs
Bunnik, E. M., de Jongh, D., & Massey, E. K. (2022) · Transplant International · doi:10.3389/ti.2022.10621 · Cited by 10
Skartsis, N., Müller, Y. D., & Ferreira, L. M. R. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109201 · Cited by 11
β Cell Stress and Endocrine Function During T1D: What Is Next to Discover?
Vived, C., Lee-Papastavros, A., Pereira, J. A. D. S., Peng, Y., & MacDonald, T. L. (2023) · Endocrinology · doi:10.1210/endocr/bqad162 · Cited by 10
Sims, E. K., Cuthbertson, D. D., Jacobsen, L. M., Ismail, H. M., Nathan, B. M., Herold, K. C., REDONDO, M. J., & Sosenko, J. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae048 · Cited by 11
Self-citationAlleva, D. G., Rezaee, M., Yip, L., Ren, G., Rosenberg, J., Concepcion, W., Escher, A., Shabahang, S., & Thakor, A. S. (2020) · Biomedicines · doi:10.3390/biomedicines8030053 · Cited by 10
Timing of Immunotherapy in Type 1 Diabetes: The Earlier, the Better?
Felton, J. L. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2000105 · Cited by 10
Replacing insulin with immunotherapy: Time for a paradigm change in Type 1 diabetes
Tatović, D., & Dayan, C. M. (2021) · Diabetic Medicine · doi:10.1111/dme.14696 · Cited by 12
Treatment of insulin-dependent diabetes by hematopoietic stem cell transplantation
Nikoonezhad, M., Lasemi, M. V., Alamdari, S., Mohammadian, M., Tabarraee, M., Ghadyani, M., Hamidpour, M., & Roshandel, E. (2022) · Transplant Immunology · doi:10.1016/j.trim.2022.101682 · Cited by 10
A predictive CD8+ T cell phenotype for T1DM progression
Wong, F. S., & Li, W. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0330-3 · Cited by 10
Heath, K. E., Feduska, J. M., Taylor, J. P., Houp, J. A., Botta, D., Lund, F. E., Mick, G. J., McGwin, G. G., McCormick, K. L., & Tse, H. M. (2023) · Biomedicines · doi:10.3390/biomedicines11071948 · Cited by 9
Active targeting of type 1 diabetes therapies to pancreatic beta cells using nanocarriers
Collins, J., & Farnsworth, N. L. (2025) · Diabetologia · doi:10.1007/s00125-024-06356-5 · Cited by 10
Besser, R. E. J., Campbell, F., Damazer, K., Elleri, D., Gillespie, K. M., Hambling, C. E., Martin, R., Mehta, F., Millar, S., Sachdev, P., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70117 · Cited by 10
Jörns, A., Arndt, T., Yamada, S., Ishikawa, D., Yoshimoto, T., Terbish, T., Wedekind, D., van der Meide, P. H., & Lenzen, S. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01941-8 · Cited by 9
Felton, J. L., Cuthbertson, D. D., WARNOCK, M. V., Lohano, K., Meah, F. A., Wentworth, J. M., Sosenko, J. M., Evans‐Molina, C., & for the Type 1 Diabetes TrialNet Study Group (2021) · Diabetologia · doi:10.1007/s00125-021-05573-6 · Cited by 9
100 years post-insulin: immunotherapy as the next frontier in type 1 diabetes
Pearson, J. A., McKinney, E. F., & Walker, L. S. K. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab024 · Cited by 9
O’Rourke, C., Ylescupidez, A., Bahnson, H. T., Bender, C., Speake, C., Lord, S. M., & Greenbaum, C. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac594 · Cited by 9
Self-citationComplete remission in children and adolescents with type 1 diabetes mellitus—prevalence and factors
Podoláková, K., Barák, Ľ., Jancova, E., Tárnoková, S., Podracká, Ľ., Dobiašová, Z., Škopková, M., Gašperíková, D., & Staník, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-34037-7 · Cited by 11
Metadata
- Authors
- Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., Marks, J. B., Moore, W., Moran, A., Rodriguez, H., Russell, W. E., Schatz, D., Skyler, J. S., Tsalikian, E., Wherrett, D. K., Ziegler, A.-G., & Greenbaum, C. J.
- Affiliations
- University of Miami (US)
- Children's Mercy Hospital (US)
- University of Minnesota (US)
- University of Iowa (US)
- ORCID
- Herold, Kevan C.
- Bundy, Brian N.
- Long, S. Alice
- Bluestone, Jeffrey A.
- DiMeglio, Linda A.
- Dufort, Matthew J.
- Gitelman, Stephen E.
- Gottlieb, Peter A.
- Krischer, Jeffrey P.
- Linsley, Peter S.
- Marks, Jennifer B.
- Moran, Antoinette
- Rodriguez, Henry
- Russell, William E.
- Schatz, Desmond
- Skyler, Jay S.
- Tsalikian, Eva
- Wherrett, Diane K.
- Ziegler, Anette-Gabriele
- Greenbaum, Carla J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-08-15
- Volume
- 381
- Issue
- 7
- Pages
- 603-613
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6776880
- OpenAlex
- W2948104235
- Semantic Scholar
- a5198a4024a6f0aecc74d1501dd9fd2892f98796
- Cited by
- 1,189
- References
- 48
- Citations by year
- 2026: 186 · 2025: 209 · 2024: 211 · 2023: 181 · 2022: 123 · 2021: 148 · 2020: 98 · 2019: 32
- FWCI
- 60.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085461, U01 DK085465, U01 DK085466, U01 DK085476, U01 DK085499, U01 DK085509, U01 DK103266, U01 DK103282, U01 DK106984, U01 DK107013, U01 DK107014, UC4 DK085466, UC4 DK097835, UC4 DK106993)
- JDRF
- American Diabetes Association
- The Immune Tolerance Network (UM1 AI09565)
- National Center for Research Resources, through Clinical Translational Science Awards (UL1TR000064, UL1TR000114, UL1TR000142, UL1TR000445, UL1TR001082, UL1TR001857, UL1TR001872, UL1TR002366, UL1TR002529, UL1TR002537)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- teplizumab, anti-CD3 monoclonal antibody, type 1 diabetes prevention, high-risk relatives, TIGIT, HLA-DR3, HLA-DR4, zinc transporter 8 antibodies, islet autoimmunity, lymphopenia
- MeSH terms
- Adolescent, Adult, Child, Diabetes Mellitus, Type 1, Double-Blind Method, Exanthema, Female, Glucose Tolerance Test, Humans, Lymphopenia, Male, Middle Aged, T-Lymphocytes, HLA-DR3 Antigen, HLA-DR4 Antigen, Proportional Hazards Models, CD3 Complex, Disease Progression, Lymphocyte Count, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
